Clinical study of the effectiveness of Saireito on the postoperative edema after blepharoptosis surgery

Clinical study of the effectiveness of Saireito on the postoperative edema after blepharoptosis surgery - Clinical study of the effectiveness of Saireito on the postoperative edema

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016258

Enrollment

Registered

2015-02-01

Start date

2014-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

blepharoptosis

Interventions

Saireito (EK-114, Kracie Pharma, Ltd., Tokyo, Japan) at 8.1g/day is administered for 8 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 20 years or older scheduled for surgery

Exclusion criteria

Exclusion criteria: *Have herbal remedy orally within 2weeks before surgery *Have any of the following systemic diseases: 1.Requiring continued use of oral corticosteroid therapy (>5 mg/day prednisolone equivalent) or immune-suppressing drug 2.malignant tumor 3.hepatuc failure or renal failure *6. Other patients judged by the investigator to be inappropriate as a subject of this study.

Design outcomes

Primary

Measure	Time frame
The degree of postoperative edema 1 week after blepharoptosis surgery	—

Secondary

Measure	Time frame
The degree of postoperative edema 2,4 and 8 weeks after blepharoptosis surgery	—

Countries

Japan

Contacts

Public ContactNaoki Morimoto

Kansai Medical University Department of Plastic and Reconstructive Surgery

morimotn@hirakata.kmu.ac.jp072-804-0101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026